Fig. 7

LncRNA ELFN1-AS1 promotes tumor growth and oxaliplatin resistance by suppressing MEIS1 expression. a qPCR of ELFN1-AS1 mRNA levels in CRC cells and the normal cell line 8401. b qPCR analysis of ELFN1-AS1 expression in 12 normal colorectal samples and 44 CRC samples. c, d CRC cell proliferation was evaluated by the CCK-8 assay. e GSEA plots showing that ELFN1-AS1 mRNA expression was positively correlated with DNA damage repair signatures in the TCGA CRC datasets. f, g The ELFN1-AS1 mRNA and MEIS1 protein levels were determined by qPCR and western blot, respectively. h, i CRC cell proliferation was determined by the CCK-8 assay. j, k The cell viability and the IC50 values of SW480 and HCT8 cells was evaluated by the CCK-8 following increasing concentrations of oxaliplatin treatment for 48 h. l, m Xenograft tumors derived from Caco2 cells with oe-ELFN1-AS1, oe-ELFN1-AS1 + oe MEIS1 and oe-NC (l) or HCT8 cells with sh-ELFN1-AS1, sh-ELFN1-AS1 + sh-MEIS1 and sh-NC (m) in BALB/c nude mice (n = 8). Tumor volume and weight were measured (top-left, removed xenografts; bottom-left, tumor size; top-right, weight). n, o The expression of MEIS1 and FEN1 in xenograft tumors was detected by western blot and qPCR. Data are presented as the mean ± SEM from three independent experiments. ***p < 0.001